MGI Palonosetron Study Shows Superiority To GSK Zofran; User Fee In July
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A pivotal study comparing MGI Pharma’s 5-HT3 antagonist palonosetron to GlaxoSmithKline’s market leader Zofran shows superior efficacy for palonosetron in prevention of chemotherapy-induced nausea and vomiting.